---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-038854"
form_type: "8-K"
ticker: "AKTX"
cik: "0001541157"
company_name: "Akari Therapeutics Plc"
filed_at: "2024-04-01T23:59:59+00:00"
generated_at: "2026-06-04T04:35:17.374378+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Akari Therapeutics FY2023 net loss narrows to $10M; all-stock merger with Peak Bio

## Summary
- FY2023 net loss $10.0M vs $17.7M in 2022; cash $3.8M at year-end, raised $2.0M in March 2024.
- Merger as equals with Peak Bio in all-stock transaction; combined pipeline includes ADC, NEI, nomacopan, PAS-nomacopan.
- Nomacopan Phase 3 for pediatric HSCT-TMA ongoing: 10 patients treated; orphan drug and rare pediatric disease designations.
- R&D expenses $5.5M (down 43% YoY); G&A $11.4M (down 16% YoY); additional capital planned Q2 2024.

## SEC filing metadata
- accession: 0000950170-24-038854
- form_type: 8-K
- ticker: AKTX
- cik: 0001541157
- company_name: Akari Therapeutics Plc
- filed_at: 2024-04-01T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1541157/000095017024038854/0000950170-24-038854-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1541157/000095017024038854/aktx-20240401.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-038854
- JSON: https://secwatch.observer/filing/0000950170-24-038854.json
- Plain text: https://secwatch.observer/filing/0000950170-24-038854.txt

## Key facts
- Earnings Releases
  Akari Therapeutics Plc reported the full year ended December 31, 2023 results: net income Net loss was approximately $10.0 million for the year ended December 31, 2023.
  - Period: the full year ended December 31, 2023
  - Net income: Net loss was approximately $10.0 million for the year ended December 31, 2023
  - Result: reported results
  source text: Akari Therapeutics Reports Full-Year 2023 Financial Results and Recent Highlights
  evidence_url: https://www.sec.gov/Archives/edgar/data/1541157/000095017024038854/0000950170-24-038854-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.